✦ LIBER ✦

A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

✍ Scribed by Steven C. Plaxe; John A. Blessing; George Olt; Nader Husseinzadah; Samuel S. Lentz; Koen DeGeest; Fidel A. Valea

Publisher: Springer
Year: 2002
Tongue: English
Weight: 71 KB
Volume: 50
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-002-0470-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mitoxantrone in the treatment of advance

Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (A phase II trial of the gynecologic oncology group)

✍ Hyman B. Muss; Brian N. Bundy; Howard D. Homesley; George Wilbanks 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 247 KB

Twenty-five evaluable patients with advanced non-squamous carcinoma of the uterine cervix were treated with mitoxantrone 12 mg/m 2 every three weeks. All patients had good performance status and measurable disease and'only 11 had received prior chemotherapy. One complete and one partial response wer

Cis-platinum in treatment of advanced or

Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase ii study of the gynecologic oncology group

✍ Tate Thigpen; Hugh Shingleton; Howard Homesley; Leo Lagasse; John Blessing 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB 👁 3 views

Histopathologic predictors of the behavi

Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix a gynecologic oncology group study

✍ R. J. Zaino; S. Ward; G. Delgado; B. Bundy; H. Gore; G. Fetter; P. Ganjei; E. Fr 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 911 KB

Phase II study of esorubicin (4′-deozydo

Phase II study of esorubicin (4′-deozydoxorubicin) in advanced epithelial carcinoma of the ovary:A Gynecologic Oncology Group study

✍ William P. McGuire; John A. Blessing; Michael L. Berman 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 275 KB

Twenty-six patients with advanced, measurable epithelial carcinoma of the ovary were treated with 76 courses of esorubicin at doses ranging from 20-30 mg/m2 every 3 weeks. All patients are evaluable for toxicity and response. All patients had received prior therapy including radiation therapy in 9,

Phase II trial of carboplatin and paclit

Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma : A Southwest Oncology Group study

✍ Ulka N. Vaishampayan; James R. Faulkner; Eric J. Small; Bruce G. Redman; Wayne L 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract ## BACKGROUND The purpose of the study was to assess the efficacy and toxicity of carboplatin and paclitaxel administered every 3 weeks in patients with advanced urothelial carcinoma, previously treated with cisplatin‐based therapy. ## METHODS Eligibility included metastatic or local

Phase II evaluation of three-day topotec

Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma : A Gynecologic Oncology Group study

✍ David Scott Miller; John A. Blessing; Samuel S. Lentz; D. Scott McMeekin 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract ## BACKGROUND Topotecan, administeredintravenously at a dose of 1.5 mg/m^2^ per day for 5 days every 21 days, is an established regimen in the treatment of recurrent ovarian carcinoma. Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability a